Array BioPharma (NASDAQ:ARRY) was up more than 9% in pre-market trade after reporting positive study results for its asthma treatment. The company said, ARRY-502, an oral CRTh2 antagonist, was studied in a 184-patient placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma, a population representing more than 12 million patients in…
Agenus Inc. (NASDAQ:AGEN) will release its fourth quarter and year end 2013 financial results before the market opens on March 5, 2014. Agenus Inc. (NASDAQ:AGEN) stock performance was 0.00% in last session and finished the day at $4.89. Traded volume was 0.00 shares in the last session and the average volume of the stock remained…
Citron exposes explosive findings behind the true components of Questcor Pharmaceuticals Inc (NASDAQ:QCOR) flagship drug HP Acthar Gel. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) stock performance was -9.96% in last session and finished the day at $60.75. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 2.86 million shares….
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -3.34% in last session and finished the day at $8.69. Traded volume was 1,200.00 shares in the last session and the average volume of the stock remained 26.48 million shares….
On Monday morning, it was announced that Avago Technologies (AVGO), a leader in advanced optical, analog and mixed-signal chip design, will acquire LSI Corp (LSI), a strong market participant in hard disk drive semiconductor, system-level silicon for communications and server applications and flash storage solutions. AVGO will pay $6.6 billion for LSI, or $11.15 per…
ARM Holdings reported 3Q13 results on Thursday that were above consensus estimates. On a positive note, ARMH’s license revenue continues to significantly exceed expectations, and ARM PD (Processor Division) royalty revenue continues to outperform ARM’s served available market (SAM) according to management’s guidance. Admittedly, shares are richly valued, and the market clearly wanted a perfect…
